EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals' devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Stock Information for Rafael Holdings Inc. Class B

Loading

Please wait while we load your information from QuoteMedia.